Alzheimer's Society
Jump to: content Jump to: navigation   Accessibility Contact Us Mobile Shop

Go to Graphical version

 

Active vaccination of ankyrin protein to reduce beta amyloid

Published 13 June 2012

Results of a study exploring the active vaccination of ankyrin G in mice to reduce levels of beta-amyloid which is thought to cause Alzheimer’s disease, has been published in Molecular Psychiatry.

The study explored how the presence of ankyrin G (AnkG) antibodies in the blood of people with Alzheimer's disease affected the progression of their symptoms. Findings indicated that people with more antibodies declined more slowly. The research also showed that immunisation of mouse models of Alzheimer's disease reduced the level of beta-amyloid in the brain and improved the health of brain cells. However, no effect on behaviour of the immunised mice was seen.

Alzheimer's Society comment:

'Finding a vaccine against Alzheimer's disease would be an exciting and life changing matter for people living with the condition. This study has identified an interesting new protein that appears to be linked to progression of symptoms, but this research is in very early stages. The AnkG vaccination reduced levels of beta-amyloid in mice, but there was no improvement in symptoms of Alzheimer's disease. Therefore, further research is needed in mice to see if AnkG can affect symptoms, before it would have potential to be tested in humans.'


'Research like this is essential if we are to develop treatments and ultimately a cure. This spring the Prime Minister promised to double investment into dementia research. We must now ensure this money is used to make the biggest difference possible for people with dementia.'

Dr Anne Corbett
Research Manager
Alzheimer's Society

- Ends -

 

Notes to editors:

 

 

  • One in three people over 65 will die with dementia
  • Alzheimer's Society research shows that 800,000 people in the UK have a form of dementia, more than half have Alzheimer's disease. In less than ten years a million people will be living with dementia. This will soar to 1.7 million people by 2051
  • Alzheimer's Society champions the rights of people living with dementia and the millions of people who care for them
  • Alzheimer's Society works in England, Wales and Northern Ireland
  • Alzheimer's Society supports people to live well with dementia today and funds research to find a cure for tomorrow. We rely on voluntary donations to continue our vital work. You can donate now by calling 0845 306 0898 or visiting alzheimers.org.uk
  • Alzheimer's Society provides a National Dementia Helpline, the number is 0845 300 0336 or visit alzheimers.org.uk